CalciMedica secures investment from Bering Partners II, with the fund acquiring 1,450,267 units at $0.8033 each, indicating a strategic partnership. The investment enhances Bering's stake to 6.9% with rights to Series A and Series B warrants.
PUBLIC · CALCJul 03, 2026
Amount Raised
$1.17 Million
Round Type
Series A
La JollaBiotechnologyHealthcare
Investors
Bering Partners II, L.P.
Description
Bering Partners II, L.P. disclosed a 6.9% stake in CalciMedica after purchasing 1,450,267 units in a recent private placement. The fund is positioned to act further as it raised its warrant ownership cap to 19.99%. This move allows for potential future investments or selling of shares depending on market conditions
Who to call at CalciMedica, and when
A new round usually means CalciMedica is about to hire and buy. The teams that reach out first get the meeting.
An alert the day CalciMedica raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at CalciMedica, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at CalciMedica. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
CalciMedica
Location
505 COAST BOULEVARD SOUTH
La Jolla, California, United States
About
CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard’s Center for Blood Research in Cambridge, MA. Dr. Stauderman’s work includes the discovery of the role of STIM1, which works in concert with Orai1 in the CRAC channels targeted by CalciMedica’s drugs. The Company has a portfolio of highly selective CRAC channel inhibitor drugs that it is developing to improve outcomes for patients with acute inflammatory indications. It has also assembled a portfolio of patents and patent applications covering those compounds as well as different aspects of CRAC channel biology.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment CalciMedica raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
La JollaBiotechnologyHealthcare